Monitoring and Prevention of Relapse after Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Bacher, Ulrike ^a   Talano, Julie An ^b   Bishop, Michael R ^c  

^a UNIVERSITY OF HAMBURG   (Germany)

^b Medical College of Wisconsin ^*  (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Acute myeloid leukemia; Minimal residual disease; Molecular markers; Monitoring; Myelodysplastic syndrome; Prevention; Relapse

Indexed keywords

AZACITIDINE; BCR ABL PROTEIN; BUSULFAN; CD33 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DENDRITIC CELL VACCINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; TREOSULFAN; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DISEASE SURVEILLANCE; DONOR LYMPHOCYTE INFUSION; GENE MUTATION; GRAFT FAILURE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MORTALITY; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEPHROBLASTOMA; PEDIATRICS; PRIMARY PREVENTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION DOSE; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855410095     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.028     Document Type: Article

References (60)

1. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
2. Pavletic S.Z., Kumar S., Mohty M., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant 2010, 16:871-890.
3. Kröger N., Bacher U., Bader P., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010, 16:1187-1211.
4. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
5. Kaeda J., O'Shea D., Szydlo R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006, 107:4171-4176.
6. Elmaagacli A.H., Beelen D.W., Kroll M., Trzensky S., Stein C., Schaefer U.W. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998, 21:159-166.
7. Bacher U., Badbaran A., Fehse B., Zabelina T., Zander A.R., Kröger N. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009, 37:135-142.
8. Schnittger S., Kern W., Tschulik C., et al. Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. Blood 2009, 114:2220-2231.
9. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. NEngl J Med 2009, 361:1058-1066.
10. Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011, 29:1373-1381.
11. Paschka P., Schlenk R.F., Gaidzik V.I., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28:3636-3643.
12. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011, 29:1190-1197.
13. Kebriaei P., Kline J., Stock W., et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 2005, 35:965-970.
14. Candoni A., Toffoletti E., Gallina R., et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 2011, 25:308-316.
15. Diez-Campelo M., Perez-Simon J.A., Perez J., et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 2009, 84:149-152.
16. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
17. Thol F., Friesen I., Damm F., et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011, 29:2499-2506.
18. Dicker F., Haferlach C., Sundermann J., et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010, 24:1528-1532.
19. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
20. Smith A.E., Mohamedali A.M., Kulasekararaj A., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116:3923-3932.
21. Bejar R., Stevenson K., bdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
22. Tamaki H., Ogawa H., Ohyashiki K., et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999, 13:393-399.
23. Lange T., Hubmann M., Burkhardt R., et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011, 25:498-505.
24. Baccarani M., Castagnetti F., Gugliotta G., Palandri F., Soverini S. Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol 2009, 22:331-341.
25. Asnafi V., Rubio M.T., Delabesse E., et al. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2006, 20:793-799.
26. Rubnitz J.E., Inaba H., Dahl G., et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010, 11:543-552.
27. Tsukimoto I., Tawa A., Horibe K., et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 Trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009, 27:4007-4013.
28. van der Velden V.H.J., van der Sluijs-Geling A., Gibson B.E.S., et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010, 24:1599-1606.
29. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
30. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
31. Scquizzato E., Zambello R., Teramo A., et al. KIR/HLA-I mismatching and risk of relapse in paediatric patients undergoing non-haploidentical allogeneic haematopoietic stem cell transplantation. Pediatr Transplant 2011, 15:198-204.
32. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
33. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
34. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
35. Brunstein C.G., Wagner J.E., Weisdorf D.J., et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009, 113:5628-5634.
36. Gropp M., Meier W., Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 1998, 71:94-98.
37. Munkelt D., Koehl U., Kloess S., et al. Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients. Cancer Chemother Pharmacol 2008, 62:821-830.
38. Shimoni A., Hardan I., Shem-Tov N., Rand A., Yerushalmi R., Nagler A. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 2007, 48:2352-2359.
39. Nemecek E.R., Guthrie K.A., Sorror M.L., et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 2011, 17:341-350.
40. Casper J., Wolff D., Knauf W., et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 2010, 28:3344-3351.
41. Jeha S., Gandhi V., Chan K.W., et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103:784-789.
42. Jeha S., Razzouk B., Rytting M., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2009, 27:4392-4397.
43. Geyer M.B., Ricci A.M., Harrison L., et al. Dose escalation of clofarabine in combination with cytarabine and total body irradiation (TBI) followed by allogeneic stem cell transplantation (AlloSCT) in children, adolescents and young adults (CAYA) with poor-risk acute leukemia. Blood 2010, 116:36.
44. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
45. Sievers E.L., Larson R.A., Stadtmauer E.A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244-3254.
46. Cairo M., Ricci A.M., Bhatia M., Duffy D., Cooney-Qualter E., Morris E., Harrison L., Schwartz J., Lowe L., Satwani P. Targeted Immunotherapy with Gemtuzumab Ozogamicin During conditioning and post allogeneic stem cell transplantation in children and adolescents with poor and average risk AML/MDS. Pediatr Blood Cancer 2011, 57:227.
47. Oka Y., Tsuboi A., Fujiki F., et al. " Cancer antigen WT1 protein-derived peptide" -based treatment of cancer-toward the further development. Curr Med Chem 2008, 15:3052-3061.
48. Keilholz U., Letsch A., Busse A., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
49. van Tendeloo V.F., van de Velde A., Van Driessche A., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010, 107:13824-13829.
50. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990, 76:1867-1871.
51. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
52. Farag S.S., Wood L.L., Schwartz J.E., et al. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 2011, 25:599-605.
53. Matthews D.C., Appelbaum F.R., Eary J.R., et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999, 94:1237-1247.
54. Pagel J.M., Gooley T.A., Rajendran J., et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009, 114:5444-5453.
55. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
56. Gill S., Olson J.A., Negrin R.S. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant 2009, 15:765-776.
57. Nakasone H., Kanda Y., Takasaki H., et al. Kanto Study Group for Cell Therapy. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia 2010, 24:1236-1239.
58. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
59. Alyea E.P., DeAngelo D.J., Moldrem J., et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:1037-1069.
60. Kohlmann A., Grossmann V., Schindela S., Kern W., Haferlach C., Haferlach T., Schnittger S. Ultra-deep next-generation sequencing detects RUNX1 mutations with unprecedented sensitivity and allows to monitor minimal residual disease in 116 samples from MDS and AML patients. ASH Annu Meet Abstr 2010, 116:1691.